医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Guangzhou Bio-Gene Announces Oral Presentation at the 2021 ASCO Annual Meeting

2021年06月03日 PM09:08
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Guangzhou Bio-Gene, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies, today announced the company will present at the 2021 American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place June 4-8th, 2021.

The presentation, entitled “The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: a multi-center interim analysis” will highlight Phase I clinical data demonstrating the safety and efficacy of BG1805, a potent anti-CLL1 CAR-T therapy, in R/R AML pediatric patients. An abstract of the presentation is currently available on ASCO website (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.10000).

Presentation details are as follows:

Session Title:

 

 

 

Pediatric Oncology I

Session Date and Time:

 

 

 

June 5, 2021, 10:00 AM – 1:00 PM

About Guangzhou Bio-Gene

Guangzhou Bio-Gene is a clinical-stage biopharmaceutical company focused on innovative oncology therapeutics. Bio-Gene is developing a pipeline of autologous and allogeneic CAR-T therapies for the treatment of a broad range of cancers and other diseases. The company is headquartered in Guangzhou, China.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005396/en/

CONTACT

Guangzhou Bio-Gene

Guangchao Li, PhD

Senior Director, Business Development

info@gzbiogene.com

www.gzbiogene.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • AGICキャピタルがATECファーマテクニックの過半数持ち分を取得
  • Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
  • 辉凌基于微生物群的首创活体生物治疗药物REBYOTA®(粪便微生物群,live-jslm)获得美国FDA批准
  • Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit
  • Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium